 | • レポートコード：MRC2304D141 • 出版社/出版日：Transparency Market Research / 2023年1月10日 • レポート形態：英文、PDF、182ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、一酸化窒素吸入デリバリーシステムの世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、種類別（小児用、成人用）分析、用途別（低酸素性呼吸不全治療、急性血管反応検査、肺高血圧症治療、その他）分析、エンドユーザー別（病院、外来手術センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、Mallinckrodt、Santair AE、VERO Biotech、Linde plc、Beyond Air, Inc.、SLE、Bellerophon Therapeutics、Air Liquide Healthcare、International Biomedical、Circassia Pharmaceuticalsなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の一酸化窒素吸入デリバリーシステム市場規模：種類別 - 小児用一酸化窒素吸入デリバリーシステムの市場規模 - 成人用一酸化窒素吸入デリバリーシステムの市場規模 ・世界の一酸化窒素吸入デリバリーシステム市場規模：用途別 - 低酸素性呼吸不全治療における市場規模 - 急性血管反応検査における市場規模 - 肺高血圧症治療における市場規模 - その他用途における市場規模 ・世界の一酸化窒素吸入デリバリーシステム市場規模：エンドユーザー別 - 病院における市場規模 - 外来手術センターにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の一酸化窒素吸入デリバリーシステム市場規模：地域別 - 北米の一酸化窒素吸入デリバリーシステム市場規模 - ヨーロッパの一酸化窒素吸入デリバリーシステム市場規模 - アジア太平洋の一酸化窒素吸入デリバリーシステム市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Inhaled Nitric Oxide Delivery System Market – Scope of Report
TMR’s report on the global inhaled nitric oxide delivery system market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global inhaled nitric oxide delivery system market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global inhaled nitric oxide delivery system market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the inhaled nitric oxide delivery system market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global inhaled nitric oxide delivery system market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global inhaled nitric oxide delivery system market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global inhaled nitric oxide delivery system market.
The report delves into the competitive landscape of the global inhaled nitric oxide delivery system market. Key players operating in the global inhaled nitric oxide delivery system market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global inhaled nitric oxide delivery system market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market inhaled nitric oxide delivery system.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Inhaled Nitric Oxide Delivery System Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of applications of iNO in pediatric as well as in adults
5.2. Technological Advancements
5.3. Disease prevalence and incidence globally with key countries
5.4. Covid-19 Impact Analysis
6. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Pediatric
6.3.2. Adult
6.4. Market Attractiveness Analysis, by Type
7. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Hypoxemic Respiratory Failure Treatment
7.3.2. Acute Vasoreactivity Testing
7.3.3. Pulmonary Hypertension (PH) Treatment
7.3.4. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Inhaled Nitric Oxide Delivery System Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East
9.3. Market Attractiveness Analysis, by Region
10. North America Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Pediatric
10.2.2. Adult
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Hypoxemic Respiratory Failure Treatment
10.3.2. Acute Vasoreactivity Testing
10.3.3. Pulmonary Hypertension (PH) Treatment
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Pediatric
11.2.2. Adult
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Hypoxemic Respiratory Failure Treatment
11.3.2. Acute Vasoreactivity Testing
11.3.3. Pulmonary Hypertension (PH) Treatment
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Pediatric
12.2.2. Adult
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Hypoxemic Respiratory Failure Treatment
12.3.2. Acute Vasoreactivity Testing
12.3.3. Pulmonary Hypertension (PH) Treatment
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Pediatric
13.2.2. Adult
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Hypoxemic Respiratory Failure Treatment
13.3.2. Acute Vasoreactivity Testing
13.3.3. Pulmonary Hypertension (PH) Treatment
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East Inhaled Nitric Oxide Delivery System Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Pediatric
14.2.2. Adult
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Hypoxemic Respiratory Failure Treatment
14.3.2. Acute Vasoreactivity Testing
14.3.3. Pulmonary Hypertension (PH) Treatment
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & South Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Mallinckrodt
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Santair AE
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. VERO Biotech
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Linde plc
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Beyond Air, Inc.
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. SLE
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Bellerophon Therapeutics
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Air Liquide Healthcare
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. International Biomedical
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Circassia Pharmaceuticals
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments